Investor Relations





         Nasdaq: PRPH
speaker_notes

Latest Presentations

Latest News

View Press Release
View All News

Latest Financial Results

Q2 2024

Quarter Ended Jun 30, 2024
Earnings Release
PDF HTML
Audio
Earnings Webcast
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Report Links

Company Overview

ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes developing a potentially life-saving cancer test focused on early detection of esophageal cancer. Our world-class, CLIA certified labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives.  We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach.

View Management Team View Board of Directors

Investor Contact Information

Company

ProPhase Labs, Inc.
711 Stewart Ave
Suite 200
Garden City, NY 11530

Investor Relations

Institutional Investor Relations
T: 267-880-1111
investorrelations@prophaselabs.com

Retail Investor Relations
John Boidman
Renmark Financial Communications
T: 514-939-3989
jboidman@renmarkfinancial.com